Cognizant Partners with Organon to Accelerate Pharmaceutical Delivery and Improve Women’s Health
Organon manufacturing site efficiency expected to improve supply chain management and accelerate delivery of healthcare products
TEANACK, NJ, July 21, 2022 /PRNewswire/ — Cognizant (NASDAQ: CTSH) today announced that it has signed a new multi-year agreement with Organon (NYSE: OGN), a global women’s health company, to help improve the delivery of health products and the the company’s crucial medical supply management.
Through this agreement, Cognizant will help scale Organon’s healthcare business by providing comprehensive industry technology support for the company’s global pharmaceutical manufacturing sites in the UK, Netherlands, Belgium and Indonesia. This includes managing Organon’s manufacturing systems with SAP’s S4/HANA suite of enterprise applications. Additionally, by providing remote and onsite support teams to increase real-time visibility into the manufacturing process and ensure continuity of pharmaceutical development, Cognizant seeks to help Organon improve supply chain oversight, increase drug yields, reduce cycle times and get products to patients faster.
“Technology is an important pillar of differentiation for Organon in fulfilling our mission to become the global leader in women’s health,” said Rachel Stahler, Director of Information Systems at Organon. “By partnering with Cognizant, we have partnered with one of the world’s leading technology and professional services companies to advance our digital ambitions and capabilities, while accelerating access to therapies important to women. of the whole world.”
“Our work with Organon to align its pharmaceutical development with Industry 4.0 principles is critical to supporting women’s health in an efficient, timely and compliant approach,” said Surya Gummadi, Senior Vice President of Health Sciences. Cognizant Global and Senior Vice President, Americas. “Partnerships like ours will help create new opportunities for companies to transform their businesses and deliver quality healthcare at scale.”
Today, Cognizant works with each of the world’s 30 largest pharmaceutical companies. Its acquisition of Zenith Technologies in 2019 allowed Cognizant to become one of the only global organizations capable of providing end-to-end support for pharmaceutical manufacturing systems. Cognizant-Zenith Technologies’ combined expertise offers a range of Industry 4.0 capabilities, including sensor and machine controller instrumentation, supervisory control, data acquisition, and automation. The majority of Organon’s manufacturing and supply program will be managed and supported by leveraging Cognizant-Zenith’s capabilities.
Cognizant (Nasdaq: CTSH) designs modern enterprises. We help our clients modernize technology, reinvent processes and transform experiences so they can stay ahead of our rapidly changing world. Together, we make everyday life better. See how to www.cognizant.com or @cognizant.